autologous hematopoietic cell transplantation

Cardiotoxicity of high-dose chemotherapy and autologous hematopoietic cell transplantation in patients with hematological malignancies

COMPLICATIONS OF ANTITUMOR TREATMENT , ,

V.O. Sarzhevsky, D.S. Kolesnikova, V.Ya. Mel’nichenko, and V.P. Tyurin

N.I. Pirogov National Medico-surgical Centre, RF Ministry of Health, Moscow, Russian Federation

ABSTRACT

This review presents the recent data on cardiotoxicity of high-dose chemotherapy and autologous hematopoietic cell transplantation in patients with hematological malignancies. The article includes detailed description of the methods used for cardiotoxicity assessment and clinical features of early and late cardiac complications. Also, the approaches to prevention and treatment of cardiotoxicity in this group of patients are suggested.

Keywords: cardiotoxicity, high-dose chemotherapy, autologous hematopoietic cell transplantation.

Read in PDF (RUS)pdficon

REFERENCES

  1. Phillips G.L., Reece D.E. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease. Clin. Haematol. 1986; 15(1): 151–66.
  2. Appelbaum F.R., Sullivan K.M., Buckner C.D. et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 1987; 5(9): 1340–7.
  3. Cazin B., Gorin N.C., Laporte J.P. et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57(10): 2061–9.
  4. Goldberg M.A., Antin J.H., Guinan E.C. et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68(5): 1114–8.
  5. Murdych T., Weisdorf D.J. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant. 2001; 28(3): 283–7.
  6. Dolci A., Dominici R., Cardinale D. et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am. J. Clin. Pathol. 2008; 130(5): 688–95.
  7. Cardinale D., Sandri M.T., Martinoni A. et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. 2000; 36(2): 517–22.
  8. Cardinale D., Sandri M.T., Colombo A. et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109(22): 2749–54.
  9. Chung T., Lim W.C., Sy R. et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart 2008; 94(7): 911–8.
  10. Horacek J.M., Pudil R., Tichy M. et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp. Oncol. 2007; 29(3): 243–7.
  11. Auner H.W., Tinchon C., Linkesch W. et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol. 2003; 82(4): 218–22.
  12. Cardinale D., Colombo A., Sandri M.T. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 2006; 114(23): 2474–81.
  13. Кардиология. Национальное руководство: краткое издание. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2012. [Kardiologiya. Natsionalnoye rukovodstvo: kratkoye izdaniye. Pod red. Yu.N. Belenkova, R.G. Oganova (Cardiology. National manual: brief edition. Ed. by Yu.N. Belenkova and R.G. Oganova). M.: GEOTAR-Media, 2012.]
  14. Suzuki T., Hayashi D., Yamazaki T. et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 1998; 136(2): 362–3.
  15. Nousiainen T., Jantunen E., Vanninen E. et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur. J. Haematol. 1998; 61(5): 347–53.
  16. Snowden J.A., Hill G.R., Hunt P. et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000; 26(3): 309–13.
  17. Masuko M., Ito M., Kurasaki T. et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern. Med. 2007; 46(9): 551–5.
  18. Zver S., Zadnik V., Bunc M. et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2007; 85(5): 408–14.
  19. Kupari M., Volin L., Suokas A. et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990; 5(2): 91–8.
  20. Styler M.J., Topolsky D.L., Crilley P.A. et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant. 1992; 10(5): 435–8.
  21. Munker R., Lazarus H. M., Atkinson K. The BMT Data Book, 2nd ed. Cambridge: Cambridge University Press, 2009: 237.
  22. Pihkala J., Saarinen U.M., Lundstrom U. et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant. 1994; 13(2): 149–55.
  23. Zver S., Zadnik V., Cernelc P. et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2008; 88(2): 227–36.
  24. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). М., 2010: 428. [Minimalnye klinicheskiye rekomendatsii Yevropeyskogo obshchestva meditsinskoy onkologii (ESMO) (Minimal clinical recommendations of European Society for Medical Oncology (ESMO)). M., 2010: 428.]
  25. Nagueh S.F., Sua H., Kopelen H.A. et al. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J. Am. Coll. Cardiol. 2001; 37: 278–85.
  26. Шкляева А.В. Ультразвуковая оценка функционального состояния левого желудочка сердца при высокодозной немиелоаблативной химиотерапии у больных злокачественными лимфомами: Автореф. дис. ¼ канд. мед. наук. Обнинск, 2011.
  27. [Shklyayeva A.V. Ultrazvukovaya otsenka funktsionalnogo sostoyaniya levogo zheludochka serdtsa pri vysokodoznoy nemiyeloablativnoy khimioterapii u bolnykh zlokachestvennymi limfomami: Avtoref. dis. ¼ kand. med. nauk (Ultrasound evaluation of left ventricle function during high-dose nonmyeloablative chemotherapy in patients with malignant lymphomas. Author’s summary of dissertation for the degree of PHD). Obninsk, 2011.]
  28. Kuittinen T., Husso-Saastamoinen M., Sipola P. et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin’s lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2005; 36(12): 1077–82.
  29. Bosch X., Esteve J., Sitges M. et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J. Card. Fail. 2011; 17(8): 643–8.
  30. Gustavsson A., Eskilsson J., Landberg T. et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann. Oncol. 1990; 1: 355–63.
  31. Girinsky T., Cordova A., Rey A. et al. Thallium-201 scintigraphy is not predictive of late cardiac complications in patients with Hodgkin’s disease treated with mediastinal radiation. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1503–6.
  32. Glanzmann C., Kaufmann P., Jenni R. et al. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother. Oncol. 1998; 46: 51–62.
  33. Salloum E., Jillella A.P., Nadkarni R. et al. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998; 82(8): 1506–12.
  34. Hertenstein B., Stefanic M., Schmeiser T. et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J. Clin. Oncol. 1994; 12(5): 998–1004.
  35. Herbay A., Dorken B., Mall G. et al. Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. Klin. Wochenschr. 1988; 66(23): 1175–81.
  36. Bearman S.I., Petersen F.B., Schor R.A. et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990; 5(3): 173–7.
  37. Lehmann S., Isberg B., Ljungman P. et al. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000; 26(2): 187–92.
  38. Armenian S.H., Sun C.L., Shannon T. et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118(23): 6023–9.
  39. Schouten H.C., Maragos D., Vose J. et al. Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation. Bone Marrow Transplant. 1990; 6(5): 333–5.
  40. Atkinson K. (ed.) Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd ed. Cambridge: Cambridge University Press, 2000: 1111.
  41. Stillwell E.E., Wessler J.D., Rebolledo B.J. et al. Retrospective outcome data for hematopoietic stem cell transplantation in patients with concurrent coronary artery disease. Biol. Blood Marrow Transplant. 2011; 17(8): 1182–6.
  42. Tyndall A., Passweg J., Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann. Rheum. Dis. 2001; 60(7): 702–7.
  43. Eckman P.M., Bertog S.C., Wilson R.F. et al. Ischemic cardiac complications following G-CSF. Catheter. Cardiovasc. Interv. 2010; 76(1): 98–101.
  44. Nakane T., Nakamae H., Koh H. et al. Heart rate variability during and after peripheral blood stem cell leukapheresis in autologous transplant patients and allogeneic transplant donors. Int. J. Hematol. 2010; 91(3): 478–84.
  45. Ulrickson M., Aldridge J., Kim H.T. et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol. Blood Marrow Transplant. 2009; 15(11): 1447–54.
  46. Reece D.E., Nevill T.J., Sayegh A. et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16–213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant. 1999; 23(11): 1131–8.
  47. Rosenthal M.A., Grigg A.P., Sheridan W.P. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leuk. Lymphoma 1994; 14(3–4): 279–83.
  48. Kim J.W., Lee H.J., Yi H.G. et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am. J. Hematol. 2012; 87(5): 479–83.
  49. Ferrara F., Palmieri S., Pedata M. et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol. Oncol. 2009; 27(1): 40–5.
  50. Krishnan G.S., Chaudhary V., Al-Janadi A. et al. BCNU toxicity presenting with a large pericardial and pleural effusion. Ann. Transplant. 2008; 13(1): 44–7.
  51. Mileshkin L.R., Seymour J.F., Wolf M.M. et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk. Lymphoma 2005; 46(11): 1575–9.
  52. Sirohi B., Powles R., Treleaven J. et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000; 25(5): 533–9.
  53. Davis J., Rowley S.D., Santos G.W. Toxicity of autologous bone marrow graft infusion. Prog. Clin. Biol. Res. 1990; 333: 531–40.
  54. Galmes A., Gutierrez A., Sampol A. et al. Long-term hematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at 80 degrees C in a mechanical freezer. Haematologica 2007; 92(7): 986–9.
  55. Rapoport A.P., Rowe J.M., Packman C.H. et al. Cardiac arrest after autologous marrow infusion. Bone Marrow Transplant. 1991; 7(5): 401–3.
  56. Martino M., Morabito F., Messina G. et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996; 81(1): 59–61.
  57. Donmez A., Zoghi M., Cagirgan S. et al. The effect of hematopoietic progenitor cells’ temperature on cardiac arrhythmias in patients given peripheral blood progenitor cells. Transfus. Apher. Sci. 2006; 34(3): 245–51.
  58. Quinn J.P., Counts G.W., Meyers J.D. Intracardiac infections due to coagulase-negative Staphylococcus associated with Hickman catheters. Cancer 1986; 57(5): 1079–82.
  59. Martino P., Micozzi A., Venditti M. et al. Catheter-related right-sided endocarditis in bone marrow transplant recipients. Rev. Infect. Dis. 1990; 12(2): 250–7.
  60. Philip T., Biron P., Herve P. et al. Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin’s malignant lymphoma with a very bad prognosis. Eur. J. Cancer Clin. Oncol. 1983; 19(10): 1371–9.
  61. Guerin C., Billard J.L., Jaubert J. et al. Pericardial aspergillosis in a bone marrow transplant recipient. Intens. Care Med. 1989; 15(5): 330.
  62. Ellerbroek P., Kuipers S., Rozenberg-Arska M. et al. Oerskovia xanthineolytica: a new pathogen in bone marrow transplantation. Bone Marrow Transplant. 1998; 22(5): 503–5.
  63. Bhatia S., Robison L.L., Francisco L. et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105(11): 4215–22.
  64. Lavoie J.C., Connors J.M., Phillips G.L. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106(4): 1473–8.
  65. Ruiz-Soto R., Sergent G., Gisselbrecht C. et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 2005; 104(12): 2735–42.
  66. Silber J.H., Cnaan A., Clark B.J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 2004; 22(5): 820–8.
  67. Lipshultz S.E., Lipsitz S.R., Sallan S.E. et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 2002; 20(23): 4517–22.
  68. Kakavas P.W., Ghalie R., Parrillo J.E. et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant. 1995; 15(6): 859–61